The European Medicines Agency (EMA) has recommended a booster dose of Johnson & Johnson’s novel coronavirus vaccine two months after the first.
The EMA said that giving a booster dose to adults 2 months after the first dose increases the amount of antibodies in the body.
The risk of thrombosis and thrombocytopenia or other side effects after taking the additional dose has not been established, and such risks are being closely monitored, the regulator said.
The EMA also noted that Johnson & Johnson’s vaccine can be administered as a booster dose after two doses of mRNA produced by Pfizer-BioNTech and Moderna.
EMA solutions are guidelines for EU member states. EU countries are independent in deciding how to vaccinate their populations in accordance with health systems.
